Company Directory / biotech/health
Public · NASDAQ:ANLFor profitbiotech/healthChina
Adlai Nortye
Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.
- Founded
- 2016 10 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $293M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
10 years old.
Reach
No web traffic ranking listed.
What it does
BiotechnologyHealth CareOncologyPharmaceutical
Funding, as listed
$293M currency not stated
- Rounds5
- LatestPost ipo equity, Sept 2023
- Investors15, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Adlai Nortye, field by field. Contact details are held but never shown.
The company
- Name
- Adlai Nortye
- Type
- For profit
- Status
- Public · NASDAQ:ANL
- Founded
- 2016
- Founders
- Carsten Lu
- Industry
- biotech/health
- Categories
- Biotechnology, Health Care, Oncology, Pharmaceutical
Where
- Country
- China
- Markets
- Asia-Pacific (APAC)
Size and reach
- Staff band
- 51-100
Funding, as listed
- Total
- 293,000,000 (currency not stated)
- Rounds
- 5
- Latest round
- Post ipo equity
- Latest round date
- Sept 2023
- Investors
- 15
- Lead investors
- 4
- Stock listing
- NASDAQ:ANL
- Listing status
- public
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Adlai Nortye may be growing as indicated by the surge in its stock price by 13%, which suggests a positive market response to the company's performance or prospects. Additionally, the fact that individual investors, who own a significant portion of the company's shares, have profited, implies that the company's valuation has increased. Despite some fluctuations in the stock price, with shares gapping up to $12.40 and down to $14.80, the overall trend includes a notable surge, which can be reflective of growth in investor confidence and potentially the company's financial health.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotech/health in China.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 38,667 companies in China and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.